AstraZeneca slashes jobs, Euro sales and marketing posts impacted

Share this article:

AstraZeneca said it plans to eliminate an additional 4,600 jobs in Europe and North America as part of a major cost-cutting initiative aimed at helping save the company $900 million by 2010.

CEO David Brennan told reporters the new cuts would include 1,800 European sales and marketing jobs, 700 research and development positions, and 1,800 business infrastructure posts.
 
The company previously announced plans for 3,000 job cuts in February at its first-quarter results. That original number was changed today to 3,300.

In total, the cuts amount to 7,600 staff, or nearly 12% of the company's workforce, compared to the 3,000 originally planned.

An AstraZeneca spokeswoman did not specify to MM&M how many US positions would be eliminated but did say that US sales and marketing positions should not be impacted.

Countries affected by the cuts include the US, Britain, Germany France and Canada.

Meanwhile, AstraZeneca's second-quarter pharmaceutical sales increased 6% to $7.3 million.

Nexium sales in the second-quarter were unchanged at $1.3 billion.

Seroquel sales increased 11% to $963 million in the second-quarter. 
 
Crestor sales in the second-quarter were up 38% to $678 million. Sales in the US were up 30%. Sales in other markets were up 47%.

Arimidex sales increased 10% in the second-quarter.

Symbicort sales were up 25% to $414 million, including $30 million in stocking sales in the US ahead of the launch on June 25. Sales in other markets were up 15%.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...